Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review.

MLA

Lei Chen, et al. “Neoadjuvant Savolitinib Targeted Therapy for Stage IIIB-N3 Lung Adenocarcinoma Harboring Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation: A Case Report and Literature Review.” Anti-Cancer Drugs, vol. 35, no. 5, June 2024, pp. 445–49. EBSCOhost, https://doi.org/10.1097/CAD.0000000000001581.

APA

Lei Chen, Jin-Feng Chen, Jin-Tao He, Hao Rong, Xiang Zhuang, & Jun Peng. (2024). Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review. Anti-Cancer Drugs, 35(5), 445–449. https://doi.org/10.1097/CAD.0000000000001581

Chicago

Lei Chen, Jin-Feng Chen, Jin-Tao He, Hao Rong, Xiang Zhuang, and Jun Peng. 2024. “Neoadjuvant Savolitinib Targeted Therapy for Stage IIIB-N3 Lung Adenocarcinoma Harboring Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation: A Case Report and Literature Review.” Anti-Cancer Drugs 35 (5): 445–49. doi:10.1097/CAD.0000000000001581.